drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Recombinant bispecific monoclonal antibody targeting CD38 and CD47; blocks the CD47–SIRPα checkpoint to enhance macrophage-mediated phagocytosis and engages CD38 on malignant plasma/B cells to mediate ADCC and CDC; administered intravenously weekly (0.01–6 mg/kg).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific monoclonal antibody targeting CD47 and CD38. By blocking the CD47-SIRPa checkpoint it promotes macrophage-mediated phagocytosis of tumor cells, and by binding CD38 on malignant plasma/B cells it engages Fc effector functions to induce ADCC and complement-dependent cytotoxicity, leading to depletion of CD38-positive tumor cells and relief of immunosuppression.
drug_name
SG2501
nct_id_drug_ref
NCT05293912